EP2526199A4 - Procédés de production de nucléases en doigt de zinc ayant une activité modifiée - Google Patents

Procédés de production de nucléases en doigt de zinc ayant une activité modifiée

Info

Publication number
EP2526199A4
EP2526199A4 EP11735277.3A EP11735277A EP2526199A4 EP 2526199 A4 EP2526199 A4 EP 2526199A4 EP 11735277 A EP11735277 A EP 11735277A EP 2526199 A4 EP2526199 A4 EP 2526199A4
Authority
EP
European Patent Office
Prior art keywords
methods
zinc finger
catalytic activity
zfn
altered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11735277.3A
Other languages
German (de)
English (en)
Other versions
EP2526199A2 (fr
Inventor
Iii Carlos F Barbas
Jing Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP2526199A2 publication Critical patent/EP2526199A2/fr
Publication of EP2526199A4 publication Critical patent/EP2526199A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP11735277.3A 2010-01-22 2011-01-21 Procédés de production de nucléases en doigt de zinc ayant une activité modifiée Withdrawn EP2526199A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29759810P 2010-01-22 2010-01-22
US32903510P 2010-04-28 2010-04-28
PCT/US2011/022154 WO2011091324A2 (fr) 2010-01-22 2011-01-21 Procédés de production de nucléases en doigt de zinc ayant une activité modifiée

Publications (2)

Publication Number Publication Date
EP2526199A2 EP2526199A2 (fr) 2012-11-28
EP2526199A4 true EP2526199A4 (fr) 2013-08-07

Family

ID=44307625

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11735277.3A Withdrawn EP2526199A4 (fr) 2010-01-22 2011-01-21 Procédés de production de nucléases en doigt de zinc ayant une activité modifiée

Country Status (2)

Country Link
EP (1) EP2526199A4 (fr)
WO (1) WO2011091324A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660642A (zh) * 2012-04-24 2012-09-12 西北农林科技大学 一种筛选锌指蛋白的筛选***
EP3289104B1 (fr) 2015-04-29 2020-11-04 New York University Procédé pour le traitement de gliomes de haut grade
US20210047633A1 (en) * 2017-03-29 2021-02-18 Editas Medicine, Inc. Selection methods
WO2018227114A1 (fr) 2017-06-09 2018-12-13 Editas Medicine, Inc. Nucléases cas9 modifiées
CN108118059B (zh) * 2017-12-30 2021-03-19 苏州金唯智生物科技有限公司 一种改进的启动子及其组成的载体和应用
US20220403553A1 (en) * 2019-09-12 2022-12-22 Glaxosmithkline Intellectual Property Development Limited Method for screening libraries
AU2021263745A1 (en) 2020-04-28 2022-12-08 Intellia Therapeutics, Inc. Methods of in vitro cell delivery
US20230416709A1 (en) * 2020-11-06 2023-12-28 Editforce, Inc. Foki nuclease domain mutant
MX2023007465A (es) 2020-12-23 2023-08-18 Intellia Therapeutics Inc Composiciones y metodos para modificar geneticamente ciita en una celula.
CR20230320A (es) 2020-12-23 2023-10-23 Intellia Therapeutics Inc Composiciones y métodos para reducir los hla-a en una célula
AU2021411521A1 (en) 2020-12-30 2023-08-03 Intellia Therapeutics, Inc. Engineered t cells
AU2022258733A1 (en) 2021-04-17 2023-11-30 Intellia Therapeutics, Inc. Inhibitors of dna-dependent protein kinase and compositions and uses thereof
EP4322920A1 (fr) 2021-04-17 2024-02-21 Intellia Therapeutics, Inc. Compositions de nanoparticules lipidiques
BR112023021445A2 (pt) 2021-04-17 2024-01-23 Intellia Therapeutics Inc Composições de nanopartículas lipídicas
WO2023205148A1 (fr) 2022-04-19 2023-10-26 Intellia Therapeutics, Inc. Compositions de récepteurs antigéniques chimériques et utilisations
TW202409271A (zh) 2022-06-16 2024-03-01 美商英特利亞醫療公司 用於減少細胞中之ｍｈｃ １類之組成物及方法
WO2024006955A1 (fr) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Lymphocytes t modifiés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139898A2 (fr) * 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Demi-domaines résultant de clivage par génie génétique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0307383B1 (pt) * 2002-01-23 2019-12-31 The Univ Of Utah Research Foundation método de recombinação genética direcionada em célula de planta hospedeira
WO2006121703A2 (fr) * 2005-05-06 2006-11-16 The Board Of Trustees Of The University Of Illinois Cartographie de nouveaux sites pour action antibiotique dans le ribosome
EP2568048A1 (fr) * 2007-06-29 2013-03-13 Pioneer Hi-Bred International, Inc. Procédés de modification du génome d'une cellule de plante monocotylédone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139898A2 (fr) * 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Demi-domaines résultant de clivage par génie génétique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Structure-Based Engineering of the FokI DNA Cleavage Domain in the Context of a Chimeric Endonuclease: Towards Maximally Efficient ''Gene Editing'' Therapy", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 9, 1 May 2004 (2004-05-01), pages 272, XP004635080, ISSN: 1525-0016 *
JING GUO ET AL: "Directed Evolution of an Enhanced and Highly Efficient FokI Cleavage Domain for Zinc Finger Nucleases", JOURNAL OF MOLECULAR BIOLOGY, vol. 400, no. 1, 4 May 2010 (2010-05-04), pages 96 - 107, XP055065197, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2010.04.060 *
MANI M ET AL: "Design, engineering, and characterization of zinc finger nucleases", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 335, no. 2, 23 September 2005 (2005-09-23), pages 447 - 457, XP027230194, ISSN: 0006-291X, [retrieved on 20050811], DOI: 10.1016/J.BBRC.2005.07.089 *
URNOV F D ET AL: "Highly efficient endogenous human gene correction using designed zinc-finger nucleases", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 435, no. 7042, 2 June 2005 (2005-06-02), pages 646 - 651, XP002411069, ISSN: 0028-0836, DOI: 10.1038/NATURE03556 *

Also Published As

Publication number Publication date
WO2011091324A8 (fr) 2012-08-30
EP2526199A2 (fr) 2012-11-28
WO2011091324A3 (fr) 2011-12-22
WO2011091324A2 (fr) 2011-07-28

Similar Documents

Publication Publication Date Title
EP2526199A4 (fr) Procédés de production de nucléases en doigt de zinc ayant une activité modifiée
MX2018007519A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
NZ750938A (en) Regulation of gene expression using engineered nucleases
WO2012166997A3 (fr) Réacteur électrochimique et procédé associé
TR201909754T4 (tr) Tüketilir bir parçayı devre dışı bırakmak için araca sahip bir aerosol üretici sistem.
MX2012007709A (es) Variantes de alfa-amilasa con estabilidad mejorada.
EA201171335A1 (ru) Вектор гена
MX2019012772A (es) Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn.
EP3613852A3 (fr) Évaluation et amélioration de la spécificité de clivage des nucléases
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
WO2010107493A3 (fr) Modification de cxcr4 en utilisant des protéines à doigt de zinc modifiées
MX353621B (es) Variantes de alfa-amilasa.
MX351043B (es) Metodos para modificacion genomica.
SG10201809564YA (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
MX2012008490A (es) Alteracion genomica dirigida.
EP2750225A4 (fr) Mélange d'électrode négative ou électrolyte sous forme de gel et batterie utilisant ledit mélange d'électrode négative ou ledit électrolyte sous forme de gel
NZ701099A (en) Ketol-acid reductoisomerase enzymes and methods of use
MX2015012484A (es) Mutaciones de acetil-coa carboxilasa.
WO2013059582A3 (fr) Inhibiteurs à petite molécule d'histone désacétylases
EP2667435A4 (fr) Matériau de mélange de graphite et de carbone, matériau de carbone pour électrode de batterie, et batterie
WO2011160052A3 (fr) Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence
MX349801B (es) Sustratos de enzimas de ácido nucleico.
WO2012061022A3 (fr) Utilisation d'un catalyseur cuivre-nickel pour la déshalogénation de composés chlorofluorés
NZ603029A (en) New methods for isolating tr1 cells
SG195170A1 (en) Methods of treating or preventing rheumatic disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120813

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130710

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/14 20060101ALI20130704BHEP

Ipc: C12Q 1/34 20060101AFI20130704BHEP

Ipc: C12N 15/55 20060101ALI20130704BHEP

Ipc: C07K 14/47 20060101ALN20130704BHEP

Ipc: C12N 15/10 20060101ALN20130704BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20140917